business

US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition

Font size+Author:World Whispers news portalSource:politics2024-05-22 02:06:27I want to comment(0)

WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the b

WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.

The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.

Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.

Related articles
  • Yvette Fielding says her Most Haunted co

    Yvette Fielding says her Most Haunted co

    2024-05-22 01:52

  • Election 2024: Republican candidates vying for Indiana governor to take debate stage

    Election 2024: Republican candidates vying for Indiana governor to take debate stage

    2024-05-22 01:14

  • Police clear out a migrant camp in central Paris. Activists say it's a pre

    Police clear out a migrant camp in central Paris. Activists say it's a pre

    2024-05-22 00:56

  • Columbia switches to hybrid learning amid protests over Israel's war in Gaza

    Columbia switches to hybrid learning amid protests over Israel's war in Gaza

    2024-05-21 23:27

Netizen comments